12:11 PM
 | 
Mar 01, 2019
 |  BC Week In Review  |  Financial News  |  Completed Offerings

Blackstone, Novartis spin out cardiovascular newco Anthos

Leading its first deal since acquiring Clarus Ventures, Blackstone has partnered with Novartis AG (NYSE:NVS; SIX:NOVN) to launch Anthos Therapeutics Inc. (Cambridge, Mass.) with $250 million and Novartis antithrombotic MAA868.

In exchange for the compound, Novartis will retain an undisclosed minority stake in the company.

MAA868 is an inhibitor of Factor XI and Factor XIa, which are part of the intrinsic coagulation pathway. According to BioCentury's BCIQ database, the...

Read the full 324 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >